Delcath selects Quintiles to support EU launch of Chemosat
Delcath Systems, an ongology-focused pharmaceutical company, has selected Quintiles to provide a specialized team of Medical Science Liaisons (MSLs) to support the launch of the Hepatic Chemosat Delivery System for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the U.K.
"This agreement gives us a highly professional medical science team in Europe with which we can begin communicating to and educating medical oncologists and liver specialists on the benefits of chemosaturation therapy," said Eamonn P. Hobbs, president and CEO of Delcath.
Comprised of medical doctors, nurses, pharmacologists and Ph.D. cancer specialists, the MSL team will draw on their understanding of the local healthcare environment and solid key opinion leader relationships to educate medical oncologists and hepatology specialists on the clinical benefits of the Chemosat system.
"The complexities in the European health care market can pose significant operational and market-place risk for companies based internationally and looking to launch here,” said Chris Pepler, head of commercial services in Europe, Middle East and Africa, Quintiles. “We're drawing on this local experience, alongside our consistent global standards of quality and delivery to provide comprehensive commercial solutions as Delcath launches their product in multiple markets across Europe."
Quintiles will also provide medical communication to support patient advocacy, key opinion leader development and field force materials.